secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001396814-24-000097
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira Q2 2024: Revenue $178M, GAAP EPS $0.39; CMS proposes EXPAREL outpatient reimbursement under NOPAIN
--------------------------------------------------------------------------------

- Total revenues of $178.0M, up 5% YoY; EXPAREL sales $136.9M (+1.3%), ZILRETTA $30.7M.
- GAAP net income $18.9M ($0.39 diluted EPS) vs $25.8M ($0.51) in Q2 2023.
- Non-GAAP net income $44.2M ($0.89 diluted EPS) vs $36.0M ($0.71) a year ago; adjusted EBITDA $62.1M.
- CMS proposed rule would separately reimburse EXPAREL in HOPD/ASC starting Jan 2025 under NOPAIN Act.
- Full-year 2024 revenue guidance reiterated at $680M-$705M; $150M share repurchase program ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681424000097/0001396814-24-000097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681424000097/pcrx-20240730.htm
  HTML page:      https://secwatch.observer/filing/0001396814-24-000097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer